926206-19-1 Usage
General Description
2-[4-(3-OXOBUTYL)PHENOXY]ACETIC ACID is a chemical compound with the molecular formula C14H16O5. It is an organic compound belonging to the class of benzyl ethers and ketones. The compound is synthesized by the reaction of 4-(3-oxobutyl)phenol with chloroacetic acid, resulting in the formation of the phenoxyacetic acid derivative. 2-[4-(3-OXOBUTYL)PHENOXY]ACETIC ACID is commonly used as a starting material in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the field of medicinal chemistry and drug development. Additionally, it may also be used as a research tool in organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 926206-19-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,6,2,0 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 926206-19:
(8*9)+(7*2)+(6*6)+(5*2)+(4*0)+(3*6)+(2*1)+(1*9)=161
161 % 10 = 1
So 926206-19-1 is a valid CAS Registry Number.
926206-19-1Relevant articles and documents
Benzoyl 2-methyl indoles as selective PPARγ modulators
Acton III, John J.,Black, Regina M.,Jones, A. Brian,Moller, David E.,Colwell, Lawrence,Doebber, Thomas W.,MacNaul, Karen L.,Berger, Joel,Wood, Harold B.
, p. 357 - 362 (2007/10/03)
A series of selective PPARγ modulators (SPPARγMs) and their development from hPPARγ active screening leads 1 and 2 is described. SPPARγM 24 displayed robust anti-diabetic activity with an improved therapeutic window in comparison to a PPARγ full agonist in a rodent efficacy model. Routine screening for human PPAR ligands yielded compounds 1 and 2, both of which were sub-micromolar hPPARγ agonists. Synthetic modifications of these leads led to a series of potent substituted 3-benzyl-2-methyl indoles, a subset of which were noted to be selective PPARγ modulators (SPPARγMs). SPPARγM 24 displayed robust anti-diabetic activity with an improved therapeutic window in comparison to a PPARγ full agonist in a rodent efficacy model.
